Cartesian Therapeutics (RNAC) EBIT (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly EBIT of -$26.5 million for Q1 2026, down 21.06% year-over-year from -$33.6 million in Q1 2025, and up 66.3% quarter-over-quarter from -$78.6 million in Q4 2025.
Cartesian Therapeutics (RNAC) EBIT (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported EBIT for 12 consecutive years, with -$26.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 21.06% year-over-year to -$26.5 million; the TTM figure through Mar 2026 stood at -$148.0 million (down 182.27% YoY), while the FY2025 annual figure was -$143.4 million, down 226.69% from the prior year.
- EBIT grew to -$26.5 million in Q1 2026 per RNAC's latest filing, from -$78.6 million in the prior quarter.
- Across five years, EBIT topped out at $13.9 million in Q2 2022 and bottomed at -$78.6 million in Q4 2025.
- Historically, EBIT has averaged -$16.8 million across 5 years, with a median of -$18.4 million in 2023.
- Annual changes were most pronounced in 2022 — EBIT surged 2966.37% — and 2023, when it plunged 717.07%.
- Cartesian Therapeutics' EBIT stood at -$8.5 million in 2022, then sank by 327.64% to -$36.3 million in 2023, then climbed by 26.43% to -$26.7 million in 2024, then plunged by 194.19% to -$78.6 million in 2025, then surged by 66.3% to -$26.5 million in 2026.
- Business Quant data shows RNAC's EBIT at -$26.5 million in Q1 2026, -$78.6 million in Q4 2025, and -$21.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | -29.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.16 Mn |
| Mar 31, 2026 | -26.50 Mn |
| Dec 31, 2025 | -78.64 Mn |
| Sep 30, 2025 | -21.07 Mn |
| Jun 30, 2025 | -21.81 Mn |
| Mar 31, 2025 | -21.89 Mn |
| Dec 31, 2024 | -26.73 Mn |
| Sep 30, 2024 | -17.58 Mn |
| Jun 30, 2024 | 13.76 Mn |
| Mar 31, 2024 | -13.35 Mn |
| Dec 31, 2023 | -36.33 Mn |
| Sep 30, 2023 | -13.07 Mn |
| Jun 30, 2023 | -18.64 Mn |
| Mar 31, 2023 | -18.38 Mn |
| Dec 31, 2022 | -8.50 Mn |
| Sep 30, 2022 | -1.60 Mn |
| Jun 30, 2022 | 13.86 Mn |
| Mar 31, 2022 | 10.77 Mn |
| Dec 31, 2021 | 4.08 Mn |
| Sep 30, 2021 | -1.97 Mn |